Precision Scientific

About Precision Scientific

Precision Scientific, established in 2015 and based in Beijing, operates as a translational medicine company focused on oncology. The firm provides comprehensive Contract Research Organization (CRO) services aimed at advancing cancer care.

The company was founded by individuals including Dr. Xuwo Ji, who serves as the CEO. Dr. Ji holds a Ph.D. in Bioinformatics from Peking University and has over a decade of investment experience in healthcare and life sciences. This background in both the scientific and financial aspects of healthcare provides the foundation for the company's strategy.

Precision Scientific's business model centers on its proprietary AI-driven platform, AIBERT® (AI-driven Big data analytics for Effective Response of cancer Therapy). This technology utilizes machine learning algorithms to perform multi-omics data mining, providing data-driven insights for oncology research and drug development. The company generates revenue by offering integrated CRO services to biotechnology and pharmaceutical companies, as well as academic and healthcare institutions. These services span drug target discovery, biomarker identification, indication selection, investigation of drug resistance mechanisms, and recommendations for combination therapies. The company's offerings also include central laboratory services, companion diagnostic development, and support with regulatory strategy and commercialization.

The company has secured significant financial backing, raising a total of $34.4M. A notable Series B funding round in September 2021 brought in $23.2M, with participation from investors such as ShenZhen GTJA Investment Group, Grand Mount Capital, and Maison Capital. A subsequent Series B1 round occurred in January 2022. These investments support the company's mission to partner with global clients in the pharmaceutical industry and deliver clinical diagnostic services to hospitals, ultimately advancing the field of precision medicine.